Company / Revenue per Share
ORAMED PHARMACEUTICALS INC. Revenue per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$0.05
FY2025
5-year range
$0.03 / $0.11
FY2021-FY2025
Trend
+50.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue per Share returned to growth in FY2025 after 4 years of decline, reaching $0.05.
Based on SEC 10-K filings.
0.05 in FY2025 with a 5-year CAGR of -20.3%.
Declined from $0.07 to $0.05 over the past 2 years.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- -10.9%
- 5-Year CAGR
- -20.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, revenue per share increased 50.8% year-over-year.
- Peak revenue per share was recorded in FY2020.
- Lowest revenue per share in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.05 | +50.8% |
| FY2024 | $0.03 | -51.4% |
| FY2023 | $0.07 | -3.6% |
| FY2022 | $0.07 | -38.1% |
| FY2021 | $0.11 | -26.4% |
| FY2020 | $0.16 | +10.0% |
| FY2019 | $0.14 | +201.5% |
| FY2018 | $0.05 | -3.5% |
| FY2017 | $0.05 | -12.3% |
| FY2016 | $0.06 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026